SK Bioscience joins US Ebola vaccine project worth up to $99M

SK Bioscience will take part in a BARDA (HHS) project to develop a vaccine against Bundibugyo virus, with up to $99 million in funding and $36 million already confirmed. IAVI and the Hilleman Institute lead the program, while SK Bioscience and its German subsidiary IDT Biologika handle manufacturing.

• BARDA support totals up to $99M, with an initial $36M tranche confirmed
• DR Congo had 10,060 Ebola cases and 4,887 deaths as of October 25
• The vaccine uses the rVSV platform behind the approved Zaire Ebola shot
• SK Bioscience handles scale-up and mass production via IDT Biologika